Yi Ge1, Zilan Wang2, Feng Gu3, Xingyu Yang2, Zhouqing Chen2, Wanli Dong4,5, Zhong Wang2. 1. Department of Neurology, The First Affiliated Hospital of Soochow University, Jiangsu Province, 188 Shizi Street, Suzhou, 215006, China. 2. Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Jiangsu Province, 188 Shizi Street, Suzhou, 215006, China. 3. First Clinical Medical School, Soochow University, Suzhou, 215006, Jiangsu Province, China. 4. Department of Neurology, The First Affiliated Hospital of Soochow University, Jiangsu Province, 188 Shizi Street, Suzhou, 215006, China. dwlscu@163.com. 5. Department of Neurology, Dushuhu Public Hospital Affiliated To Soochow University, Jiangsu Province, Suzhou, 215006, China. dwlscu@163.com.
Abstract
BACKGROUND: To evaluate the safety and efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) in the treatment of Parkinson's disease (PD). METHODS: The databases of Medline, EMBASE, and the Cochrane Library were searched for eligible randomized controlled trials comparing focused ultrasound surgery (FUS) group vs. sham procedure group in PD. Weighted mean differences and standardized mean differences with corresponding 95% confidence intervals were used to summarize the primary outcome, namely, the effect of MRgFUS to improve limb tremor in PD patients and adverse events, and the secondary outcome, which is the effect of MRgFUS in improving the quality of life, activities of daily living, and non-motor symptoms. RESULTS: The pooled analysis comprised 2 studies. The blinded phase lasted for 4 months in one experiment and up to 3 months in the other. The FUS group showed significant improvement in limb tremor on the treated side (SMD: - 1.20; 95% CI: - 2.06, - 0.34) and the ability to perform daily activities (SMD: - 0.86; 95% CI: - 1.41, - 0.32) compared to the sham group, but there were no significant group differences in other indicators. Of the process-related adverse events, dizziness (OR: 4.68; 95% CI: 1.20, 18.23) was more common in the treatment group, with no group differences in the remaining adverse events. CONCLUSIONS: These findings suggest beneficial effects of MRgFUS in PD patients with no serious side effects. Larger multicenter studies are needed in the future to select the most appropriate target and surgical device setup parameters.
BACKGROUND: To evaluate the safety and efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) in the treatment of Parkinson's disease (PD). METHODS: The databases of Medline, EMBASE, and the Cochrane Library were searched for eligible randomized controlled trials comparing focused ultrasound surgery (FUS) group vs. sham procedure group in PD. Weighted mean differences and standardized mean differences with corresponding 95% confidence intervals were used to summarize the primary outcome, namely, the effect of MRgFUS to improve limb tremor in PD patients and adverse events, and the secondary outcome, which is the effect of MRgFUS in improving the quality of life, activities of daily living, and non-motor symptoms. RESULTS: The pooled analysis comprised 2 studies. The blinded phase lasted for 4 months in one experiment and up to 3 months in the other. The FUS group showed significant improvement in limb tremor on the treated side (SMD: - 1.20; 95% CI: - 2.06, - 0.34) and the ability to perform daily activities (SMD: - 0.86; 95% CI: - 1.41, - 0.32) compared to the sham group, but there were no significant group differences in other indicators. Of the process-related adverse events, dizziness (OR: 4.68; 95% CI: 1.20, 18.23) was more common in the treatment group, with no group differences in the remaining adverse events. CONCLUSIONS: These findings suggest beneficial effects of MRgFUS in PD patients with no serious side effects. Larger multicenter studies are needed in the future to select the most appropriate target and surgical device setup parameters.
Authors: Aaron E Bond; Binit B Shah; Diane S Huss; Robert F Dallapiazza; Amy Warren; Madaline B Harrison; Scott A Sperling; Xin-Qun Wang; Ryder Gwinn; Jennie Witt; Susie Ro; W Jeffrey Elias Journal: JAMA Neurol Date: 2017-12-01 Impact factor: 18.302
Authors: W Jeffrey Elias; Nir Lipsman; William G Ondo; Pejman Ghanouni; Young G Kim; Wonhee Lee; Michael Schwartz; Kullervo Hynynen; Andres M Lozano; Binit B Shah; Diane Huss; Robert F Dallapiazza; Ryder Gwinn; Jennifer Witt; Susie Ro; Howard M Eisenberg; Paul S Fishman; Dheeraj Gandhi; Casey H Halpern; Rosalind Chuang; Kim Butts Pauly; Travis S Tierney; Michael T Hayes; G Rees Cosgrove; Toshio Yamaguchi; Keiichi Abe; Takaomi Taira; Jin W Chang Journal: N Engl J Med Date: 2016-08-25 Impact factor: 91.245
Authors: Marc N Gallay; David Moser; Franziska Rossi; Anouk E Magara; Maja Strasser; Robert Bühler; Milek Kowalski; Payam Pourtehrani; Christian Dragalina; Christian Federau; Daniel Jeanmonod Journal: Front Surg Date: 2020-01-14
Authors: Mario Stanziano; Nico Golfrè Andreasi; Giuseppe Messina; Sara Rinaldo; Sara Palermo; Mattia Verri; Greta Demichelis; Jean Paul Medina; Francesco Ghielmetti; Salvatore Bonvegna; Anna Nigri; Giulia Frazzetta; Ludovico D'Incerti; Giovanni Tringali; Francesco DiMeco; Roberto Eleopra; Maria Grazia Bruzzone Journal: Front Neurol Date: 2022-01-12 Impact factor: 4.003